Canonical Wnt Pathway Inhibitor ICG-001 Induces Cytotoxicity of Multiple Myeloma Cells in Wnt-Independent Manner
Fig 6
In vivo effect of ICG-001 on MM tumor burden.
(A) MM tumors were established in SCID-beige mice by subcutaneous inoculation of RPMI-8226 cells. In ~ 3 weeks, mice were split into 2 groups (4 mice/group) and treated with either vehicle control (PBS) or 100 mg/kg ICG-001 twice a day. Tumor growth was monitored by measuring tumor size twice a week. Two-way ANOVA was used to analyze the difference between the 2 groups. (B, C) MM tumors were established in NSG mice by intravenous inoculation of RPMI-8226-dsRed2 cells. In 2 weeks mice were randomly assigned to 2 groups and treated with either vehicle control (vc; n = 3) or ICG-001 (n = 4). (B) Tumor burden was evaluated by measuring dsRed2 protein fluorescence using IVIS 200 In Vivo Imaging System 3 weeks after start of the treatment. (C) Onset of hunched posture and hind leg paralysis has been evaluated and compared between groups.